Bioavailability Study for New Atorvastatin Formulation
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the relative bioavailability of the commercial
tablet with one prototype extemporaneous preparation suspension formulation, to assist with
internal decision making on formulation development.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.